Related Experiment Video
Updated: Aug 7, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Tensor-Based Multi-Modality Feature Selection and Regression for Alzheimer's Disease Diagnosis
Jun Yu1, Zhaoming Kong1, Liang Zhan2
1Department of Computer Science and Engineering, Lehigh University, Bethlehem, Pennsylvania, USA.
Summary
This study introduces a new tensor-based method for diagnosing Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) using multi-modality brain imaging. The approach improves diagnostic accuracy and identifies key biomarkers.
Area of Science:
- Neuroimaging
- Biomarker Discovery
- Machine Learning in Medicine
Background:
- Accurate assessment of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) using brain imaging is challenging.
- Combining multi-modality imaging techniques enhances the reflection of pathological characteristics for improved AD and MCI diagnosis.
Purpose of the Study:
- To propose a novel tensor-based multi-modality feature selection and regression method for AD and MCI diagnosis.
- To identify diagnostic biomarkers for AD and MCI by leveraging high-level correlations in multi-modality data.
Main Methods:
- Utilized a tensor structure to exploit correlations within multi-modality data (VBM-MRI, FDG-PET, AV45-PET).
- Investigated tensor-level sparsity in a multilinear regression model for feature selection and diagnosis.
- Applied the method to ADNI data, incorporating clinical parameters of disease severity and cognitive scores.
Main Results:
- The proposed method demonstrated superior performance compared to state-of-the-art approaches for disease diagnosis.
- Successfully identified disease-specific brain regions and modality-related differences.
- Validated practical advantages using real-world ADNI data.
Conclusions:
- The novel tensor-based multi-modality approach offers improved accuracy in diagnosing AD and MCI.
- This method is effective for biomarker identification and understanding modality-specific contributions to disease pathology.
- The publicly available code facilitates further research in neurodegenerative disease diagnostics.
Related Concept Videos
Alzheimer's Disease: Overview
575
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
575
Alzheimer's Disease: Treatment
233
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
233

